The effect of weight gain and metabolic dysfunction-associated steatotic liver disease on liver fibrosis progression and regression in people with HIV
Giovanni Guaraldi,Jovana Milic,Stefano Renzetti,Federico Motta,Felice Cinque,Jenny Bischoff,Andrea Desilani,Jacopo Conti,Filippo Medioli,Martina del Monte,Dana Kablawi,Wesal Elgretli,Stefano Calza,Cristina Mussini,Juergen K. Rockstroh,Giada Sebastiani
DOI: https://doi.org/10.1097/qad.0000000000003903
IF: 4.632
2024-04-10
AIDS
Abstract:Objective: People with HIV (PWH) have high risk of liver fibrosis. We investigated the effect of weight gain and metabolic dysfunction-associated steatotic liver disease (MASLD) on liver fibrosis dynamics. Design: Multicenter cohort study. Methods: Fibrosis progression was defined as development of significant fibrosis (liver stiffness measurement [LSM]≥8 kPa), or transition to cirrhosis (LSM≥13 kPa), for those with significant fibrosis at baseline. Fibrosis regression was defined as transition to LSM<8 kPa, or to LSM 248 dB/m) with at least one metabolic abnormality. A continuous-time multi-state Markov model was used to describe transitions across fibrosis states. Results: Among 1183 PWH included from three centres (25.2% with viral hepatitis coinfection), baseline prevalence of significant fibrosis and MASLD was 14.4% and 46.8%, respectively. During a median follow-up of 2.5 years (interquartile range 1.9–3.5) the incidence rate of fibrosis progression and regression was 2.8 (95% CI, 2.3–3.4) and 2.2 (95% CI, 1.9–2.6) per 100 person-years, respectively. In Markov model, weight gain increased the odds of fibrosis progression (odds ratio [OR] 3.11, 95% CI 1.59–6.08), whereas weight gain (OR 0.30, 95% CI 0.10–0.84) and male sex (OR 0.32, 95% CI 0.14–0.75) decreased the odds of fibrosis regression. On multivariable Cox regression analysis, predictors of fibrosis progression were weight gain (adjusted hazard ratio [aHR] 3.12, 95% CI 1.41–6.90) and MASLD (aHR 2.72, 95% CI 1.05–7.02). Conclusions: Fibrosis transitions are driven by metabolic health variables in PWH, independently of viral hepatitis coinfection and antiretroviral class therapy.
immunology,infectious diseases,virology